▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4209 by analyst upside · 2026-09-27
DNA
Ginkgo Bioworks Holdings, Inc.
Healthcare · Market Cap $718M · P/E 0x
ANALYST PRICE TARGET
-34.3%
implied upside to consensus target
Current Price $10.66
Consensus Target $7.0
Bull Target $9.0
Bear Target $5.0
Analysts Covering 2
ANALYST CONSENSUS - UNDERPERFORM
Strong Buy
0
Buy
0
Hold
1
Sell
1
52-Week Low $5.37
52-Week High $17.58
YTD Return +22.5%
FUNDAMENTALS
Market Cap $718M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-5.33
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $132M
Profit Margin -219.6%
52-WEEK RANGE
52-Week Low $5.37
52-Week High $17.58
Current Price $10.66
Bear Target $5.0
Bull Target $9.0
● Now $10.66 ● Target $7.0
TRADING DATA
Avg Volume 1.2M
YTD Return +22.5%
Analyst Count 2
Consensus Underperform
Upside to Target -34.3%
Last Updated 2026-09-27

ANALYST SUMMARY

Ginkgo Bioworks Holdings, Inc. (DNA) is currently trading at $10.66 with a Wall Street consensus price target of $7.0, which is 34.3% below the current price over the next 12 months. 2 analysts currently cover DNA, with a consensus rating of Underperform - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $9.0, while the most cautious has a target of $5.0.

DNA operates in the Healthcare sector with a market capitalisation of $718M. The stock is up 22.5% year-to-date and is currently trading near the lower end of its 52-week range of $5.37 – $17.58.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INMD +13.4%
InMode Ltd.
$821M · P/E 11.8x · Hold
ABUS +11.3%
Arbutus Biopharma Corporation
$961M · P/E 6.1x · Buy
TBPH +3.7%
Theravance Biopharma, Inc.
$884M · P/E 16.4x · Hold
RIGL +30.8%
Rigel Pharmaceuticals, Inc.
$900M · P/E 2.9x · Buy
AMPH -13.9%
Amphastar Pharmaceuticals, Inc.
$1B · P/E 15.5x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for DNA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Sell → Sell 2026-09-04 38% win rate (8 calls)
TD Cowen ↓ Downgrade
Buy → Hold 2026-08-07 Building track record
BTIG - Reiterated
Sell → Sell 2026-03-12 38% win rate (8 calls)
TD Cowen - Reiterated
Buy → Buy 2026-01-08 Building track record
BTIG - Reiterated
Sell → Sell 2025-08-25 38% win rate (8 calls)
TD Cowen - Reiterated
Buy → Buy 2024-09-20 Building track record
BTIG - Reiterated
Sell → Sell 2024-08-23 38% win rate (8 calls)
Goldman Sachs - Reiterated
Sell → Sell 2024-07-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
32
out of 100
Coverage depth
8/30
Consensus clarity
22/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →